Tag Archives: cancer research

July is Bone Cancer Awareness Month – What to Know

Picture of a bone cross section
Bone Cancer or Sarcoma is in the focus in July

What are the types of bone cancer? Can it be treated with immunotherapy for cancer programs? July is Bone Cancer Awareness Month, making it a good time to share some facts about the disease from the National Cancer Institute.

Basics of Bone Cancer

As the name implies, bone cancer is a malignant tumor that forms in bone tissue. The majority of bone tumors are benign, which means they’re non-fatal and don’t spread.

On the other hand, bone cancer CAN spread to other parts of the body. Regardless of the location of the metastasis, or spread, the disease is still referred to as bone cancer based on its original site.

Types of Bone Cancer

– Osteosarcoma, usually found in the knee or upper arm, develops in hard bone tissue.

– Chondrosarcoma forms in cartilage, which is the tough but resilient tissue that cushions joints.

– The Ewing Sarcoma Family of Tumors, or ESFTs, are thought to arise from primitive nerve tissue in bone or soft tissues.

Bone Cancer Symptoms

Chronic pain or swelling in or near a bone are the most common symptoms of bone cancer, but they could also be indicative of other conditions, so it’s important to be tested.

Treatments for Bone Cancer

Traditional treatments such as surgery and chemotherapy are often used with bone cancer patients. The NCI and other organizations also sponsor frequent clinical trials to investigate immunotherapy for cancer treatments.

Help for Patients with Stage IV Bone Cancer

Visit our website for testimonials from patients with metastasized bone cancer and other forms who have achieved long-term remission with immunotherapy for cancer at Issels®.

Cancer Gets Fuel From Fat Cells – How to Starve Tumors

It's Time to Cross Out Cancer!
It’s Time to Cross Out Cancer!

Cancer research is now going beyond the genetic aspect to explore how the disease interacts with the body’s systems. Recent studies of the relationship between cancer and fat cells may have implications concerning immunotherapy for cancer.

Feeding the Growth of Cancer Cells

While the precise causes are not yet known, obesity has been identified as a risk factor for prostate cancer, which is the second leading cause of cancer-related deaths in men. As a result, research into the link between cancer and fat cells has focused on this form of the disease.

Previous tests involved mice who were fed a high-fat diet. In contrast, researchers at Sanford Prebys Medical Discovery Institute in San Diego conducted a study using mice who lacked a protein called p62, causing them to become obese on a normal diet.

According to co-author Dr. Jorge Moscat, this control was necessary to get a clear understanding of the communication pathways between cancer and fat cells. The team discovered that p62 suppresses another protein known as mTORC1, which in turn inhibits energy use by fat cells.

Can Cancer Cells Be “Starved” to Death?

With metabolism halted in fat cells, nutrients are then available to fuel development of tumor cells. Lack of p62 also triggers production of proteins found at high levels in particularly aggressive forms of prostate cancer.

As explained by Dr. Moscat, these findings can help identify specific substances to be targeted by immunotherapy for cancer treatments with the goal of “starving” cancer cells.

State-of-the-Art Immunotherapy for Cancer at Issels®

Contact Issels® for information about our non-toxic, personally developed immunotherapy programs to treat advanced and therapy-resistant cancers.

The Importance of Gut Bacteria in the Spread of Pancreatic Cancer

The Importance of Gut Bacteria in the Spread of Pancreatic Cancer
The Importance of Gut Bacteria in the Spread of Pancreatic Cancer

Gut bacteria, or microbiome, include organisms that manufacture vitamins and promote healthy digestion and other functions. A study recently published in Cancer Discovery found that pathogenic gut bacteria can have a negative impact on pancreatic cancer treatment.

When Gut Bacteria Fights the Immune System

A research team at NYU School of Medicine conducted tests on both mice and humans with pancreatic ductal adenocarcinoma (PDA), a particularly aggressive form of pancreatic cancer. The scientists discovered that pathogenic, or “bad,” gut bacteria migrated to the pancreas, increasing bacterial presence by a thousand times.

Problems arise when this unbalanced mix of bacteria triggers a shutdown of immune cells, allowing cancer cells to multiply unchecked. Checkpoint inhibitors are a type of immunotherapy cancer treatment that reactivates immune cells, but they’re ineffective against the overwhelming amount of bacteria in the pancreas.

Using Antibiotics to Supplement Immunotherapy

When the researchers treated the mice with antibiotics, the amount of bacteria decreased enough to “flip the switch” on immune cells, thereby slowing cancer growth. In addition, checkpoint inhibitors were approximately three times more effective when used in conjunction with antibiotics.

Checkpoint inhibitors had previously failed to treat pancreatic cancer in clinical trials, so scientists are encouraged by these results. The team is now recruiting PDA patients to test the antibiotic-checkpoint inhibitor combo.

Issels®: Cancer Treatment Harnessing the Power of the Immune System

Our non-toxic immunotherapy programs focus on helping your body’s own immune system attack and kill cancer cells. These personally tailored treatments have fewer side effects and work to eliminate the causes that create tumors. Contact us for more information.

Robots May Soon be Performing Lung Laparoscopies for Cancer Detection

Robots May Soon be Performing Lung Laparoscopies for Cancer Detection
Robots May Soon be Performing Lung Laparoscopies for Cancer Detection

Robots are becoming increasingly entrenched in manufacturing, but do they have a place in cancer treatment? Earlier this year, the FDA approved a new robotic device for use in diagnosing lung cancer.

Robotics: Building Better Surgical Devices

As a surgical resident in the early 1908s, Fred Moll became convinced that there was a better way to perform procedures. After resigning his residency, Moll went to work creating high-tech medical devices.

Today Moll has become known for his invention of the $2 million da Vinci Surgical System, which is the top-selling surgical robot used in laparoscopic procedures. Surgeons operate the device using electronic hand controls and a video monitor.

But Moll is not content to rest on his laurels. He’s certain that medical robots will eventually be able to work autonomously, without relying on a surgeon’s control.

The Future of Robotic Surgery

On March 22, the FDA approved use of the Monarch Platform, which is the first step toward Moll’s ultimate vision. The new system includes a pair of arms as well as a long tube for doctors to steer a camera and other instruments inside the patient’s body.

At this point, FDA approval covers the Monarch Platform for use by a doctor to diagnose (and eventually treat) lung cancer. According to Moll, the Monarch will be able to drive itself in as few as 18 months from now.

Issels®: The Future of Cancer Treatment Is Here Today

While immunotherapy cancer treatment is a hot topic in the scientific community today, Issels® has had years of success with our individually developed programs. Visit our website to learn more.

4 in 10 Cancers are Preventable with Lifestyle Alteration

4 in 10 Cancers are Preventable with Lifestyle Alteration
4 in 10 Cancers are Preventable with Lifestyle Alteration

Early detection greatly improves the success rate of cancer immunotherapy, but wouldn’t it be better if cancer never developed in the first place? A recent report out of the United Kingdom shows that nearly 40 percent of cancer diagnoses in that nation could be prevented with healthy lifestyle changes.

Tobacco: #1 Preventable Cause of Cancer

In March 2018, Cancer Research UK (CRUK) published a study concerning preventable causes of cancer. Based on the data, they determined that nearly four out of 10 cancer cases could be prevented. That translates to more than 2,500 new cancer diagnoses per week in the UK.

Exposure to tobacco smoke, which accounts for 15 percent of cancer cases in the UK, continued to lead the list of preventable causes. The next two factors were obesity and UV radiation exposure from the sun or tanning beds.

Changing Public Beliefs and Behaviors

CRUK’s research team applauded public anti-smoking measures such as advertising restrictions and taxes on tobacco products. They also urged similar actions to help fight the shifting trend toward overeating and obesity.

While obesity currently accounts for just over six percent of cancer cases, making it a distant second to tobacco smoke, the team cautioned that excess weight has the potential to become “the new smoking.” Prof. Linda Bauld of KRUK cited the increasing acceptability of obesity as the norm.

Integrative Cancer Immunotherapy Programs at Issels®

In addition to treating cancer and its causes, our immunobiologic core treatment includes education in nutrition and other elements of a healthy lifestyle. Visit our website to learn more about our personally developed cancer immunotherapy treatments.

Prostate Screening Using PSA Tests Appears to Miss Many Aggressive Cancers

Prostate Screening Using PSA Tests Appears to Miss Many Aggressive Cancers
Prostate Screening Using PSA Tests Appears to Miss Many Aggressive Cancers

The healthcare community has long promoted early detection as one of the keys to successful cancer treatment. In the UK, where prostate cancer is the second most common cause of cancer death in men, experts are referring to the corresponding PSA test as a “blunt tool” that has no life-saving benefit.

The Merits and Drawbacks of PSA Testing

A PSA test measures a specific protein in the blood that increases when cancer cells are present. Any man over the age of 50 in the UK can currently request a PSA test from his general practitioner.

In response to a debate about whether or not the country’s National Health Service should institute a national prostate cancer screening program, Cancer Research UK funded a study to evaluate the effectiveness of PSA testing. Subjects included 400,000 men between the ages of 50 and 69.

Results showed that death rates among men in the group were identical, regardless of whether or not they received a PSA test. The screening failed to detect several cases of aggressive prostate cancer while causing unnecessary stress by flagging benign tumors.

Should Men Undergo Prostate Cancer Screening?

Dr. Emma Turner, a member of the research team, stated the need for more accurate testing that would facilitate early prostate cancer treatment. In the meantime, Heather Blake of Prostate Cancer UK suggests that men over 50 discuss the pros and cons with their GP before opting for a PSA test.

Immunotherapy for Prostate Cancer at Issels®

Men with prostate cancer are among the many patients who have achieved long-term remission after cancer treatment at Issels®. Contact us to learn more.